HSA
NBIX icon

Hussman Strategic Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Hussman Strategic Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6M Buy
27,300
+6,300
+30% +$935K 1.06% 5
2026
Q1 		$2.77M Hold
21,000
– – 0.6% 47
2025
Q4 		$2.98M Hold
21,000
– – 0.72% 24
2025
Q3 		$2.95M Buy
+21,000
New +$2.85M 0.64% 37
2025
Q2 		– Sell
-25,200
Closed -$2.79M – 266
2025
Q1 		$2.79M Buy
25,200
+16,800
+200% +$2.13M 0.68% 37
2024
Q4 		$1.15M Sell
8,400
-23,100
-73% -$2.86M 0.34% 120
2024
Q3 		$3.63M Buy
31,500
+6,300
+25% +$864K 0.89% 17
2024
Q2 		$3.47M Buy
25,200
+14,700
+140% +$2.02M 0.96% 12
2024
Q1 		$1.45M Hold
10,500
– – 0.34% 112
2023
Q4 		$1.38M Sell
10,500
-17,900
-63% -$2.06M 0.31% 132
2023
Q3 		$3.19M Sell
28,400
-8,000
-22% -$842K 0.61% 42
2023
Q2 		$3.43M Sell
36,400
-10,100
-22% -$987K 0.63% 30
2023
Q1 		$4.71M Buy
46,500
+20,500
+79% +$2.13M 0.74% 20
2022
Q4 		$3.11M Sell
26,000
-5,200
-17% -$609K 0.51% 75
2022
Q3 		$3.31M Hold
31,200
– – 0.57% 47
2022
Q2 		$3.04M Hold
31,200
– – 0.52% 55
2022
Q1 		$2.92M Buy
31,200
+20,800
+200% +$1.76M 0.57% 55
2021
Q4 		$886K Sell
10,400
-5,100
-33% -$469K 0.19% 168
2021
Q3 		$1.49M Hold
15,500
– – 0.33% 121
2021
Q2 		$1.51M Buy
+15,500
New +$1.49M 0.31% 127
2020
Q4 		– Sell
-10,000
Closed -$962K – 299
2020
Q3 		$962K Hold
10,000
– – 0.25% 159
2020
Q2 		$1.22M Sell
10,000
-5,000
-33% -$553K 0.31% 126
2020
Q1 		$1.3M Buy
+15,000
New +$1.47M 0.35% 116
2019
Q2 		– Sell
-10,000
Closed -$881K – 231
2019
Q1 		$881K Hold
10,000
– – 0.22% 162
2018
Q4 		$714K Buy
+10,000
New +$958K 0.17% 177

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hussman Strategic Advisors's NBIX Position: Q2 2026 in Review

Hussman Strategic Advisors increased its Neurocrine Biosciences (NBIX) stake by 30% in Q2 2026, buying an estimated $935K and bringing the position to 27,300 shares worth $4.6M. The position accounts for 1.06% of the portfolio, ranked #5.

Hussman Strategic Advisors first reported a position in NBIX in Q4 2018 and has held it in 25 quarters since. The position peaked at $4.71M in Q1 2023. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Hussman Strategic Advisors held 27,300 shares of Neurocrine Biosciences worth $4.6M as of Q2 2026.
  • Hussman Strategic Advisors bought 6,300 Neurocrine Biosciences shares in Q2 2026, an estimated $935K.
  • Neurocrine Biosciences made up 1.06% of Hussman Strategic Advisors's portfolio in Q2 2026, its #5 holding.
  • Hussman Strategic Advisors first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 25 quarters since.
  • Hussman Strategic Advisors's Neurocrine Biosciences position peaked at $4.71M in Q1 2023.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.